Thursday, October 9, 2014

Impax Laboratories Inc said it was on the hunt for further deals - and would consider a so-called "tax inversion" transaction - after its acquisition of two privately held Pennsylvania drugmakers for $700 million.Impax's shares jumped as much as 17 percent to $17.85 in morning trading on the Nasdaq on Thursday.The acquisition of Lineage Therapeutics Inc and Tower Holdings Inc, both based in Horsham, Pennsylvania, gave Impax access to an emergency anti-allergen injection, epinephrine.Chief Executive Frederick Wilkinson said Hayward, California-based Impax was looking for more such deals.

Impax Laboratories Inc. is a specialty pharmaceutical company. Shares of IPXL traded higher by 10.74% or $2.56/share to $26.40. In the past year, the shares have traded as low as $19.39 and as high as $31.04. On average, 653172 shares of IPXL exchange hands on a given day and today's volume is recorded at 1790432.

Please Donate

Article Archive

The reports on this site are for information purposes only and are not a recommendation for the purchase of securities. The information contained in these reports have been gathered from sources we believe to be reliable, however, we make no guarantee as to the accuracy or completeness to such information.